Kevin Fitzpatrick will step down from his role as CEO of CancerLinQ LLC, a wholly owned non-profit subsidiarity of the American Society of Clinical Oncology, on April 13 to pursue a new opportunity outside of ASCO.
Richard Schilsky, ASCO chief medical officer, will serve as interim CEO. CancerLinQ LLC will initiate a global search for a permanent CEO to oversee the continued expansion and implementation of CancerLinQ.
“Under Kevin’s leadership we’ve taken CancerLinQ from a bold and ambitious idea to a reality for physicians and researchers across the country who seek to learn from everyday patient care,” Clifford Hudis, CEO of ASCO and chair of the CancerLinQ board of governors, said in a statement. “He played a crucial role in establishing CancerLinQ, overseeing its rollout to physician practices and securing novel strategic collaborations with government, for-profit and non-profit entities.
“We are fortunate to have Dr. Schilsky, with his extensive experience with CancerLinQ and oncology data, and his relationships throughout the oncology community, to step in to sustain our momentum through the transition,” Hudis said.
Schilsky is a past president of ASCO and has served as CMO since 2012. In addition to being closely involved with CancerLinQ since its inception. He leads ASCO’s Center for Research & Analytics, which makes various cancer data sets—including CancerLinQ Discovery—available to the oncology community and provides consultation and support for research and analysis.
Last year, ASCO and two companies—Tempus and Precision Health AI—announced a deal to curate and license the data in CancerLinQ. The ten-year collaboration, announced Dec. 21, 1017, gives Tempus and PH.AI access to de-identified data from over a growing database of more than a million records contained in CancerLinQ (The Cancer Letter, Jan. 5)